SCHEMBL6665137

SCHEMBL6665137

NC(=O)C1=CC2=CC=CCC2=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2721543 0.84
SCHEMBL1664489 0.84
SCHEMBL31392785 0.82 KDM4E (0.30)
SCHEMBL27799963 0.70
SCHEMBL9901663 0.69
SCHEMBL7746085 0.69 SLC7A5 (0.36)
SCHEMBL7746093 0.69 SLC7A5 (0.36)
SCHEMBL12496652 0.69
SCHEMBL10893931 0.66
SCHEMBL2721545 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232447-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY Evotec International GmbH (DE) 2023-08-30 EP claimed
WO-2022084447-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2022-04-28 WO claimed
EP-4396175-A1 CRYSTALLINE INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-07-10 EP disclosed
WO-2023034854-A1 CRYSTALLINE INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-03-09 WO disclosed
EP-1483240-A1 INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY AstraZeneca AB (SE) 2004-12-08 EP disclosed
WO-2003074484-A1 INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2003-09-12 WO disclosed